AtaiBeckley (ATAI) Other Operating Expenses (2020 - 2023)

AtaiBeckley (ATAI) reported Other Operating Expenses of $60.2 million for Q4 2023, up 236.78% sequentially from $17.9 million in Q4 2021.

AtaiBeckley (ATAI) Other Operating Expenses (2020 - 2023) Analysis & Trends

AtaiBeckley (ATAI) has 3 years of Other Operating Expenses data on file, last reported at $60.2 million in Q4 2023.

For the quarter ending Q4 2023, Other Operating Expenses changed N/A year-over-year to $60.2 million; the trailing twelve-month figure through Sep 2024 stood at $60.2 million (changed N/A YoY), and the FY2023 full-year result was $60.2 million, changed N/A from the prior year.
Other Operating Expenses improved to $60.2 million in Q4 2023, from $17.9 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $60.2 million in Q4 2023 to a low of -$5.5 million in Q2 2021.
A 3-year average of $12.2 million and a median of $972000.0 in 2021 frame the typical range for Other Operating Expenses.
Peak annual rise in Other Operating Expenses reached 50.22% in 2021, while the deepest fall reached 4650.0% in 2021.
Tracing ATAI's Other Operating Expenses over 3 years: stood at $11.9 million in 2020, then surged by 50.22% to $17.9 million in 2021, then jumped by 236.78% to $60.2 million in 2023.
Business Quant data shows ATAI's Other Operating Expenses at $60.2 million in Q4 2023, $17.9 million in Q4 2021, and -$70000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	AtaiBeckley	2.56 Bn	2.56 Bn	-

Download Data